Bratton Capital Management, L.P. Aquestive Therapeutics, Inc. Transaction History
Bratton Capital Management, L.P.
- $54.8 Billion
- Q3 2025
A detailed history of Bratton Capital Management, L.P. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Bratton Capital Management, L.P. holds 9,810,958 shares of AQST stock, worth $52.9 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
9,810,958
Previous 9,810,958
-0.0%
Holding current value
$52.9 Million
Previous $32.5 Billion
68.88%
% of portfolio
100.0%
Previous 100.0%
Shares
2 transactions
Others Institutions Holding AQST
# of Institutions
163Shares Held
65.9MCall Options Held
794KPut Options Held
457K-
Rtw Investments, LP New York, NY6.25MShares$33.7 Million0.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.66MShares$30.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$29.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.76MShares$20.3 Million0.05% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.63MShares$14.1 Million1.1% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $288M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...